content_copy Vitro Biopharma Obtains CLIA Certification

Vitro Biopharma Obtains CLIA Certification

August 20, 2021

Vitro Biopharma Obtains CLIA Certification

Vitro Biopharma Obtains CLIA Certification Adding a New Dimension to its Ongoing Stem Cell Clinical Trials

Golden, Colorado—April 2, 2019Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma announced receipt of a Certificate of Compliance with CLIA (Clinical Laboratory Improvement Amendment) without deficiencies.  This allows Vitro Biopharma to perform clinical laboratory testing, reporting and billing in full compliance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA) according to section 353 of the Public Health Service Act (42 C.F.R. § 263a) and (42 C.F.R § 493).

We will use our CLIA Certification to expand services related to stem cell therapies to include diagnostics as well as therapy including our patent-pending AlloRx Stem Cell™ product.  The testing includes biomarkers to assess stem cell status and the effects of stem cell therapies as well.  Assessment of stem cell status is an emerging aspect of medical diagnostics since stem cell deficiencies may underly diseases, such as MS & Alzheimer’s disease.  Also, efficiency of stem cell therapies is quantified by diagnostic tests such measurement of anti-inflammatory effects, differentiation of stem cells and reduction of autoimmunity in autoimmune diseases.  By using highly sensitive, specific and accurate tests, efficiency of therapies may be determined at higher levels of statistical significance.  The efficiency of stem cell therapies is often measured from patient assessments of joint function and pain that are subject to considerable variation.  Quantitative biomarker testing provides less variability and complements other efficacy tests to enhance measurement of stem cell clinical outcomes.

Keith Burge, Director of Sales and Marketing of Vitro Biopharma said, “Attainment of CLIA certification is continuance of Vitro’s commitment to establishing manufacturing, operating and quality standards as a world class stem cell provider.  ISO 9001 certification and cGMP compliance was instrumental in the company recently gaining approval for our Stem Cell Clinical Trial for Musculoskeletal Conditions by the Bahamas Ministry of Health.  Our ongoing IRB approved trial in the Cayman Islands with our clinical partner, DVCStem, recently provided a treatment to Lou Ferrigno, the “Incredible Hulk”, a testament to the quality to Vitro’s AlloRx product”.

Tiana Tonrey, MS and COO of Vitro Biopharma said,  “ {I would suggest our regulatory status summary, ISO, FDA reg …& expansion of operations based on CLIA certification, plans for regulatory approvals, etc}

About Vitro Biopharma: {I will update this section from prior PRs with current updates prior to publication.}

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company’s auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements”.  Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.  Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission.  Most of these factors are outside the control of the Company.  Investors are cautioned not to put undue reliance on forward-looking statements.  Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

Also in News

Pitt Hopkins FDA Trial
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat Pitt Hopkins Syndrome, a rare form of Autism

November 18, 2021 0 Comments

Golden, Colorado-November 9, 2021- Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its IND for a phase I-II, randomized, double-blind, placebo-controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in children with Pitt Hopkins Syndrome (PTHS), a rare neurogenetic disorder that features autistic traits. PTHS results from genetic mutations/deletions of a key brain development gene, TCF4 (transcription factor 4) that controls neurogenesis. 

Read More

Fitore and Infinivive logo
Vitro Biopharma Acquires Fitore Nutrition and Infinivive MD, Adding Revenues from Innovative Stem Cell Activation Products and Topical Cosmetic Stem Cell Serums

August 31, 2021 0 Comments

Golden, Colorado-August 31, 2021- Vitro Biopharma, Inc. ("Vitro') announced the acquisition of Fitore Nutrition ("Fitore") and Infinivive MD ("Infinivive"). Fitore, a private company headquartered in Denver, Colorado creates clinically validated supplements and sells them direct to consumers (D2C) via their unique digital marketing platform and SEO expertise.

Infinivive, located in Cherry Creek, Colorado developed the world's first topical cosmetic stem cell serum and is a nationally recognized company led by one of the top industry pioneers in the area of cosmetic surgery, Dr. Jack Zamora M.D.

Read More

Vitro Biopharma Signs Multi-Million Dollar Operating Service Contract with European Wellness Biomedical Group
Vitro Biopharma Signs Multi-Million Dollar Operating Service Contract with European Wellness Biomedical Group

August 20, 2021 0 Comments

Golden, Colorado-August 19, 2021-Vitro Biopharma, Inc. announced the signing of a contract with European Wellness Biomedical Group headquartered in Kuala Lumpur, Malaysia and it’s start-up subsidiary BioPep being registered in Delaware, USA to develop FDA-approval of biological products derived from existing mitochondrial peptide extracts now used globally as treatment of various conditions including aesthetic dermatology and skin revitalization, autism spectrum disorders, cardiovascular, metabolic and degenerative disorders, CKD and fertility through its global network of 12 (twelve) biomedical regenerative centers located throughout Europe and Asia Pacific. 

Read More